Today: 31 January 2026
Subscribe
Browse Category

Healthcare News 30 September 2025 - 21 October 2025

UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

Stock Price Snapshot: October 2025 Rebound UnitedHealth stock has seen volatile swings in 2025, but recent weeks brought a measure of relief. As of Oct. 21, shares trade around $364, up from the lows hit earlier in the year. On Monday (Oct. 20), UNH jumped +2.21% to close at $364.48 Investing, recovering from a mid-month dip. Over the past week…
21 October 2025
···
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) Globenewswire. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) Globenewswire. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) Globenewswire Stocktitan. Early trial data for…
21 October 2025
····
DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in after-hours trading Monday following the company’s announcement that it has acquired virtual care platform SteadyMD” Investing. The acquisition was disclosed…
21 October 2025
····
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 Stockanalysis Stockanalysis. That rally marked a new 2025 high for the biotech…
18 October 2025
····
INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

Stock Price Surge and Aftermath INVO Fertility’s stock took Wall Street by surprise this week with a massive one-day surge. On October 16, shares of the micro-cap fertility clinic operator opened around $0.75 and skyrocketed nearly 90% by day’s end, closing at approximately $1.43 ts2.tech. Intra-day, the price briefly hit $2+ per share, a huge jump from the prior day’s…
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from…
17 October 2025
···
Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Lawsuit Outcome and Court Ruling Humana (the second‐largest Medicare Advantage insurer) sued CMS in July after its star rating unexpectedly plunged. The insurer argued that CMS unfairly flagged three interpreter calls as failures (with no callback allowed), causing a 4.5-to-3.5 star drop Reuters Healthcaredive. On Oct. 14, U.S. District Judge Reed O’Connor (Northern Texas) rejected Humana’s arguments Reuters. He found…
15 October 2025
···
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company, Kenvue (KVUE). Now it is moving a second business out: the orthopedics arm of its MedTech division. The spin-off means…
14 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one…
6 October 2025
····
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis (eyelid inflammation caused by Demodex mites) Globenewswire. Tarsus reports that XDEMVY’s launch has exceeded expectations – CEO Bobak Azamian called the Q2 results their “strongest quarter to date”…
3 October 2025
····
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Stock Performance (Oct 3, 2025) As of midday Oct 3, Humana shares were $272.05, up about +6.01% on the day Reuters. Yesterday’s close (Oct 2) was $256.62 Reuters, so HUM has recovered much of last week’s slide. In fact, Oct 1 saw a ~5% drop (on news of scaling back Medicare Advantage plans) Finviz, but Oct 2’s star rating news spurred a ~3% gain Reuters.…
3 October 2025
····
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow patients to pay out-of-pocket for certain drugs, bypassing insurers and middlemen Wbtv Reuters. White House Press Secretary Karoline Leavitt confirmed…
30 September 2025
··
1 … 8 9 10 11 12

Stock Market Today

  • Bitcoin Whales Buy the Dip as Smaller Holders Sell Amid Price Drop
    January 31, 2026, 2:23 PM EST. Significant investors known as whales, holding 10,000 or more bitcoin, are accumulating the cryptocurrency despite its price falling near $78,000, according to Glassnode onchain data. The Accumulation Trend Score shows whales in a light buying phase since bitcoin's dip from $80,000 in late November, contrasting with smaller holders, especially those with under 10 BTC, who are selling amid market uncertainty. The number of entities holding over 1,000 BTC rose from 1,207 in October to 1,303, signaling that large investors are absorbing supply during this period of consolidation and price volatility.
Go toTop